Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 20171510.
- Also identified by DOI 10.1016/j.ijrobp.2009.08.076 and PMC identifier 3431963.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Biomarkers are of interest for predicting or monitoring normal tissue toxicity of radiation therapy. Advances in molecular radiobiology provide novel leads in the search for normal tissue biomarkers with sufficient sensitivity and specificity to become clinically useful. This article reviews examples of studies of biomarkers as predictive markers, as response markers, or as surrogate endpoints for radiation side effects. Single nucleotide polymorphisms are briefly discussed in the context of candidate gene and genomewide association studies. The importance of adjusting for radiation dose distribution in normal tissue biomarker studies is underlined. Finally, research priorities in this field are identified and discussed.
Medical subject headings
- Biomarkers
- Polymorphism, Single Nucleotide
- Radiation Injuries
- Radiation Tolerance
- Radiotherapy